Stock research
PHAT Phathom Pharmaceuticals, Inc.
Healthcare • Biotechnology
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a...…
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
5Y change
-71.87%
Range high
$36.83
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in PHAT?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $11.64
- Day High
- $10.21
- Day Low
- $8.80
- 52w High
- $18.31
- 52w Low
- $8.03
- Volume
- 7,610,104
- Avg Volume
- Beta
- 0.487
* TTM/most recent where available
Company
- Ticker
- PHAT
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Steven L. Basta
- Employees
- 371
- Website
- www.phathompharma.com
Key Metrics
- Market Cap
- 720M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).